Evidence map›Paper›PMID 35898335›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Integrative analysis of clinical health records, imaging and pathogen genomics identifies personalized predictors of disease prognosis in tuberculosis.

Awanti Sambarey, Kirk Smith, Carolina Chung, Harkirat Singh Arora, Zhenhua Yang, Prachi Agarwal, Sriram Chandrasekaran

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Awanti SambareyBiomedical Engineering, University of Michigan.
Kirk SmithChemical BIology, University of Michigan.
Carolina ChungBiomedical Engineering, University of Michigan.
Harkirat Singh AroraBiomedical Engineering, University of Michigan.
Zhenhua YangEpidemiology, University of Michigan.
Prachi AgarwalRadiology, Michigan Medicine.
Sriram ChandrasekaranBiomedical Engineering, University of Michigan.
University of Michigan · USMichigan Medicine · US

Funding

A multifactorial pipeline to dissect combinatorial drug efficacy in TuberculosisR01AI150826 · NIAID · UNIVERSITY OF WASHINGTON · PI SHERMAN, DAVID R · 2021 to 2024
$2.9M
A multifactorial pipeline to dissect combinatorial drug efficacy in TuberculosisR56AI150826 · NIAID · UNIVERSITY OF WASHINGTON · PI SHERMAN, DAVID R · 2020 to 2020
$733k
NIAID NIH HHS R01 AI150826NIAID NIH HHS R56 AI150826
6 · The paper itself

Abstract

Tuberculosis (TB) afflicts over 10 million people every year and its global burden is projected to increase dramatically due to multidrug-resistant TB (MDR-TB). The Covid-19 pandemic has resulted in reduced access to TB diagnosis and treatment, reversing decades of progress in disease management globally. It is thus crucial to analyze real-world multi-domain information from patient health records to determine personalized predictors of TB treatment outcome and drug resistance. We conduct a retrospective analysis on electronic health records of 5060 TB patients spanning 10 countries with high burden of MDR-TB including Ukraine, Moldova, Belarus and India available on the NIAID-TB portals database. We analyze over 200 features across multiple host and pathogen modalities representing patient social demographics, disease presentations as seen in cChest X rays and CT scans, and genomic records with drug susceptibility features of the pathogen strain from each patient. Our machine learning model, built with diverse data modalities outperforms models built using each modality alone in predicting treatment outcomes, with an accuracy of 81% and AUC of 0.768. We determine robust predictors across countries that are associated with unsuccessful treatmentclinical outcomes, and validate our predictions on new patient data from TB Portals. Our analysis of drug regimens and drug interactions suggests that synergistic drug combinations and those containing the drugs Bedaquiline, Levofloxacin, Clofazimine and Amoxicillin see more success in treating MDR and XDR TB. Features identified via chest imaging such as percentage of abnormal volume, size of lung cavitation and bronchial obstruction are associated significantly with pathogen genomic attributes of drug resistance. Increased disease severity was also observed in patients with lower BMI and with comorbidities. Our integrated multi-modal analysis thus revealed significant associations between radiological, microbiological, therapeutic, and demographic data modalities, providing a deeper understanding of personalized responses to aid in the clinical management of TB.

Indexed as

drug-resistanceEHR datamachine learningpandemicpersonalized medicineTBTuberculosisUkraine

Identifiers

PMID35898335
PMCPMC9327630
OpenAlexW4286382805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.